Denver, Colorado - VolitionRx Limited (NYSE:VNRX) unveiled promising new data that could reshape the landscape of early cancer detection, reporting over 95% sensitivity in identifying stage I and II cancers using its proprietary Capture-Seq liquid biopsy technology.
The results, drawn from a blinded validation cohort, highlight the growing potential of blood-based diagnostics to detect cancer at its earliest and most treatable stages, an area representing a massive commercial and clinical opportunity. Volition is targeting a combined total addressable market estimated at approximately $36 billion, spanning multi-cancer early detection (MCED) and minimal residual disease (MRD) monitoring.
The study evaluated 81 subjects, including 59 patients with colorectal and lung cancers and 22 healthy controls. Across all cancer stages, the test demonstrated 93% overall sensitivity and 95% specificity. Most notably, early-stage detection rates reached 94% for stage I cancers and 96% for stage II cancers, figures that stand out in a field where early detection has historically been challenging.
At the core of this advancement is Capture-Seq, a novel two-step process designed to isolate circulating tumor DNA (ctDNA) from blood samples with unprecedented purity. Traditional liquid biopsy methods struggle because the vast majority of DNA in plasma originates from healthy cells, diluting the cancer signal. Volition’s approach addresses this by combining physical enrichment techniques with advanced bioinformatic filtering, resulting in ctDNA datasets that are more than 99% pure.
This level of precision opens the door not only for early detection but also for broader applications in cancer care. Beyond screening, the technology could be used to monitor treatment response and detect minimal residual disease, key components in managing cancer progression and recurrence.
The implications extend beyond the lab. The company noted increasing interest from potential licensing partners, including major players in the liquid biopsy and diagnostics space. With ongoing discussions aimed at accelerating commercialization, Capture-Seq could eventually be integrated into both human and veterinary healthcare markets, complementing Volition’s existing Nu.Q platform.
While additional large-scale validation studies will be required, the early data positions Volition as a notable contender in the race to develop reliable, non-invasive cancer diagnostics. If these results hold, technologies like Capture-Seq™ could play a pivotal role in shifting cancer detection earlier, where outcomes are significantly improved and treatment options are more effective.